Mylan Inc.

Mylan Inc. today announced that it has completed a private placement of $300 million aggregate principal amount of Senior Notes due 2020. The notes were issued at an iss...

Mylan Inc. today announced that it has completed a private placement of $300 million aggregate principal amount of Senior Notes due 2020. The notes were issued at an iss...

Mylan Inc. today announced that it priced $300 million aggregate principal amount of Senior Notes due 2020 at an issue price of 105.5% with a coupon of 7.875%, or an eff...

Mylan Inc. today announced that it intends to privately place $300 million in aggregate principal amount of senior notes through a reopening of its Senior Notes due 2020...

Mylan Inc. today announced its financial results for the three and six months ended June 30, 2010.

Mylan Inc. today announced its financial results for the three and six months ended June 30, 2010.

Mylan Inc. announced today that it is rescheduling its second quarter earnings conference call and live webcast due to a scheduling conflict. Mylan will now review the c...

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited received final approval on July 20 from the U.S. Food and Drug Administration for its Abbrevi...

Mylan Inc. today announced that it has entered into settlement and license agreements with Forest Laboratories and Merz Pharmaceuticals related to Namenda® Tablets, 5 mg...

Mylan Inc. today announced that it has entered into settlement and license agreements with Forest Laboratories and Merz Pharmaceuticals related to Namenda® Tablets, 5 mg...